Pfizer CEO Albert Bourla Outlines Strategy to Catch Up in Obesity and Cancer Drug Development
核心洞察
Pfizer CEO Albert Bourla (搜索) acknowledged the company's post-COVID business decline and described a psychological toll on himself and the organization after moving from top to bottom performer in stock price.
Bourla said Pfizer aspires to bring an obesity treatment to market that requires monthly injections rather than weekly injections, calling it a "very big differentiation."
The CEO framed Pfizer's next ambition as replicating its COVID success in oncology, telling employees "we are going to do it again, with cancer this time."
Pfizer CEO Albert Bourla (搜索), who rose to global prominence leading the company's COVID-19 vaccine effort, is now charting a course to recover from a sharp post-pandemic decline and reposition the pharmaceutical giant around oncology and obesity. In recent interviews, Bourla candidly described the psychological impact of the downturn and outlined the strategic bets he believes will restore Pfizer's momentum.
A "Comedown" After COVID
Bourla acknowledged that the period following the pandemic represented a significant setback for Pfizer's business. "Coming out of COVID was a big comedown for Pfizer's business," he said, adding that the shift "impacted you psychologically."
"I'm a very, very high achiever. To go from the top performer to the bottom performer—although not in everything, but in stock price, for example—was something that I didn't take lightly," Bourla said. "And I know that my whole organization didn't take it lightly. I needed to find the path and rally an organization behind it."
To motivate his workforce, Bourla drew a direct parallel between the company's pandemic achievement and its next ambition. "I tried to explain to people, 'You were the guys that saved the world when nobody thought that it could be saved. And you did it in ways that nobody thought it was possible. Guess what? We are going to do it again, with cancer this time.'"
Catching Up in Obesity
Bourla conceded that Pfizer trails some competitors in the obesity market, which rivals have come to dominate. He framed Pfizer's path forward around a differentiated dosing approach.
"We aspire to bring into the market an obesity treatment that instead of weekly injections requires monthly injections," Bourla said. "That's a very big differentiation."
The company's strategic shift toward innovative medicine includes major investments in oncology and obesity, alongside high-stakes decisions behind multibillion-dollar acquisitions, according to a discussion hosted by Norges Bank Investment Management.
The Case for Speed
Bourla defended Pfizer's emphasis on speed in drug development, arguing that it does not come at the expense of rigor. "I think it is extremely important that we do things faster without cutting any corners," he said.
He invoked the company's internal motto to underscore the stakes. "We have a saying in Pfizer: 'Time is life.' Bringing medicine for a cancer patient earlier makes all the difference in the world. If that medicine will allow someone to see the wedding of the son or the graduation of the daughter, there is nothing more important in their life, and speed is what will allow them to do it."
Leadership and the Road Ahead
Beyond the business strategy, Bourla reflected on the personal dimensions of leadership, including how to build resilience, foster organizational confidence, and continuously evolve as a CEO. He also shared a deeply personal story about his mother, a Holocaust survivor, and how her perspective shaped his optimism and drive.
Looking ahead, Bourla pointed to artificial intelligence as a transformative force set to reshape drug discovery, clinical trials, and the broader healthcare system. He also offered a candid view on global competition, particularly the rapid rise of China in biotech, and what it will take for companies like Pfizer to stay ahead.